Overview

Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy

Status:
Recruiting

Trial end date:
2023-11-27

Target enrollment:

Participant gender:

Summary

The phase II, randomised Study is to explore the efficacy and safety of nivolumab as consolidation therapy in patients with locally advanced, unresectable non-small cell lung cancer (stage III) who have not progressed following neoadjuvant chemotherapy plus nivolumab and definitive concurrent chemoradiation therapy

Phase:

Phase 2

Details

Lead Sponsor:

Sun Yat-sen University

Treatments:

Nivolumab